About Krystal Biotech
Krystal Biotech (NASDAQ:KRYS) is a focused biotechnology company dedicated to developing and commercializing gene therapies for patients with serious skin diseases. Their innovative approach utilizes a proprietary gene delivery platform aiming to treat conditions with significant unmet needs. Key projects include lead candidate VYJUVEK™, designed to treat dystrophic epidermolysis bullosa, a rare and often fatal skin disorder, showcasing their dedication to transforming the treatment landscape for dermatological conditions. With a mission centered on improving patients' lives by leveraging cutting-edge science, Krystal Biotech is committed to advancing a pipeline of novel gene therapy candidates through clinical development and towards commercial readiness, prioritizing safety, efficacy, and accessibility for those in need.
Snapshot
Operations
Produtos e/ou serviços de Krystal Biotech
- VYJUVEK (beremagene geperpavec, B-VEC) for dystrophic epidermolysis bullosa, the first FDA-approved gene therapy offering hope for this rare skin disorder's effective treatment.
- KB105 for treating TGM-1 deficient autosomal recessive congenital ichthyosis, a therapy under development aimed at addressing severe skin barrier defects through gene replacement.
- KB104, a gene therapy candidate for Netherton Syndrome, focuses on delivering a functional SPINK5 gene to skin cells, aiming to restore the skin's barrier function.
- KB407 for Cystic Fibrosis, which seeks to provide a gene-based treatment to correct the underlying CFTR gene defect in lung epithelial cells, offering a novel approach to this lung disease.
- KB301 for skin rejuvenation and the treatment of fine lines and wrinkles, a novel aesthetic product aiming to promote collagen production and enhance dermal regeneration.
- KB314 for hyperhidrosis, targeting the condition's root cause through gene therapy to offer a long-term solution for excessive sweating without the need for repeat treatments.
equipe executiva do Krystal Biotech
- Mr. Krish S. Krishnan M.B.A., M.S.Founder, Chairman, President & CEO
- Ms. Suma M. KrishnanFounder, President of R&D and Director
- Ms. Kathryn A. Romano CPAExecutive VP & Chief Accounting Officer
- Mr. John ThomasGeneral Counsel & Corporate Secretary
- Mr. John KarakkalVice President of North American Sales & Marketing
- Ms. Christine WilsonHead of U.S. Sales & Marketing
- Dr. Stephane Paquette Ph.D.Vice President of Corporate Development
- Mr. Josh SuskinSenior Director & Head of US Human Resources
- Mr. Laurent GouxSenior VP & GM of Europe
- Dr. David Chien M.D.Senior Vice President of Clinical Development